10 ABT-199 Lies Unwrapped

Validation of TJ status by cross-reference against reported joint haemorrhage number resulted in the final analytic sample of 286 individuals, with 48 (17%) in the prophylaxis group and 238 (83%) in the episodic treatment group (Fig.?1). The maximum time to complete two follow-up visits after reporting a TJ by the 286 participants was 7?years; however, 96% completed two follow-up visits within two calendar years after the visit in which the TJ was reported. Demographics of the study population are shown in Table?1. Descriptive statistics were computed separately for the prophylaxis and the episodic treatment http://www.selleck.cn/products/CP-690550.html groups. Overall, the median age at development of TJ was 18?years (range 3�C77?years). Statistically significant differences were found in the age at first TJ report, BMI and the distribution of index TJs between the two groups. Individuals who received secondary prophylaxis were significantly younger (98% were http://www.selleckchem.com/products/abt-199.html TJ when compared to the episodic treatment group. Almost all individuals in the prophylaxis group were negative for hepatitis B, hepatitis C and human immunodeficiency virus (HIV). The distribution of other characteristics including race, disease severity, type of haemophilia and presence of factor inhibitor antibodies, were comparable between the prophylaxis and episodic groups. The effect of receiving secondary continuous prophylactic factor infusion therapy on three clinical outcomes was evaluated in statistical models appropriate for http://www.selleckchem.com/products/ABT-263.html the nature of the outcome variable: (i) percent ROM change after two visits following TJ development, (ii) total number of joint haemorrhages and (iii) development of any new TJs by the end of follow-up period. The unadjusted summary statistics of all three outcome variables are given in Table?2. Table?3 demonstrates the effect of age and treatment modality on the three joint outcomes. The results from the three multivariate models are summarized in Tables?4-6. Median 4, Range (0�C49) N (%) Median 15��5, Range (0�C114) N (%) As expected (Table?2), both groups experienced a drop in joint ROM in their index joints following TJ development when compared to their assessed ROM at the most recent visit before TJ development. Two years post-TJ development, both groups had improved ROM in the index joint; the prophylaxis group showed slightly more improvement in ROM as compared to the episodic group (prophylaxis 0��54%, episodic 0��05%). However, these changes in the percent ROM were not statistically different between the two groups.